Drug Search Results

FluMist

Alternative Names: FluMist
Latest Update: 2024-12-04
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Nasal

FDA Designation: None *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for FluMist

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Influenza, Human

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
2017-000849-50	P2	Active, not recruiting	Influenza, Human	2018-08-26

Recent News Events

Date	Type	Title
11/12/2024	News Article	AstraZeneca's 9M and Q3 2024 results
09/11/2024	News Article	Versatope Launches Clinical Development Team for VT-105, a Pan-influenza A Vaccine Candidate
07/25/2024	News Article	AstraZeneca's H1 and Q2 2024 Financial Results
01/01/2024	PubMed	Distinct Functional Humoral Immune Responses Are Induced after Live Attenuated and Inactivated Seasonal Influenza Vaccination.
12/05/2023	PubMed	Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine.
11/28/2023	PubMed	FDA Will Evaluate First Self-Administered FluMist Vaccine.
09/20/2023	News Article	Nasal Spray Vaccine Market Size, Top Companies, Opportunities and Forecast by 2029

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions